BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31081930)

  • 21. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
    Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
    BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Euphorbia factor L2 inhibits TGF-β-induced cell growth and migration of hepatocellular carcinoma through AKT/STAT3.
    Fan L; Zhu H; Tao W; Liu L; Shan X; Zhao M; Sun D
    Phytomedicine; 2019 Sep; 62():152931. PubMed ID: 31085375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tunicamycin inhibits cell proliferation and migration in hepatocellular carcinoma through suppression of CD44s and the ERK1/2 pathway.
    Hou H; Ge C; Sun H; Li H; Li J; Tian H
    Cancer Sci; 2018 Apr; 109(4):1088-1100. PubMed ID: 29377347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpinia oxyphylla oil induces apoptosis of hepatocellular carcinoma cells via PI3K/Akt pathway in vitro and in vivo.
    Hui F; Qin X; Zhang Q; Li R; Liu M; Ren T; Zhao M; Zhao Q
    Biomed Pharmacother; 2019 Jan; 109():2365-2374. PubMed ID: 30551496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway.
    Mao J; Wang D; Wang Z; Tian W; Li X; Duan J; Wang Y; Yang H; You L; Cheng Y; Bian J; Chen Z; Yang Y
    Cancer Lett; 2016 Sep; 380(1):134-43. PubMed ID: 27349166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TQ inhibits hepatocellular carcinoma growth in vitro and in vivo via repression of Notch signaling.
    Ke X; Zhao Y; Lu X; Wang Z; Liu Y; Ren M; Lu G; Zhang D; Sun Z; Xu Z; Song JH; Cheng Y; Meltzer SJ; He S
    Oncotarget; 2015 Oct; 6(32):32610-21. PubMed ID: 26416455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
    Wang Z; Qu L; Deng B; Sun X; Wu S; Liao J; Fan J; Peng Z
    Sci Rep; 2016 Sep; 6():33205. PubMed ID: 27628214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JARID2 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition through PTEN/AKT signaling.
    Lei X; Xu JF; Chang RM; Fang F; Zuo CH; Yang LY
    Oncotarget; 2016 Jun; 7(26):40266-40284. PubMed ID: 27259236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-tumor effect of Yanggan Huayu granule by inducing AKT-mediated apoptosis in hepatocellular carcinoma.
    Shen Y; Yang F; Peng H; Zhang G; Zhu F; Xu H; Shi L
    J Ethnopharmacol; 2022 Jan; 282():114601. PubMed ID: 34487847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. USP22 knockdown enhanced chemosensitivity of hepatocellular carcinoma cells to 5-Fu by up-regulation of Smad4 and suppression of Akt.
    Zhang J; Luo N; Tian Y; Li J; Yang X; Yin H; Xiao C; Sheng J; Li Y; Tang B; Li R
    Oncotarget; 2017 Apr; 8(15):24728-24740. PubMed ID: 28445968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.
    Xu Q; Liu X; Liu Z; Zhou Z; Wang Y; Tu J; Li L; Bao H; Yang L; Tu K
    Mol Cancer; 2017 Jun; 16(1):103. PubMed ID: 28606154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of CD29-ILK-Akt signaling-mediated epithelial-mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells.
    Jiang X; Wang J; Zhang K; Tang S; Ren C; Chen Y
    Med Oncol; 2015 May; 32(5):141. PubMed ID: 25805567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basil polysaccharide inhibits hypoxia-induced hepatocellular carcinoma metastasis and progression through suppression of HIF-1α-mediated epithelial-mesenchymal transition.
    Feng B; Zhu Y; Sun C; Su Z; Tang L; Li C; Zheng G
    Int J Biol Macromol; 2019 Sep; 137():32-44. PubMed ID: 31252022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism.
    Kim YS; Lee YM; Oh TI; Shin DH; Kim GH; Kan SY; Kang H; Kim JH; Kim BM; Yim WJ; Lim JH
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. I
    Wu L; Sun B; Lin X; Liu C; Qian H; Chen L; Yang Y; Shen F; Su C
    Genes Cells; 2018 Jan; 23(1):35-45. PubMed ID: 29210217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.